Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections.
| Autor: | Cheung, Tony W., Jayaweera, Dushyantha T., Pearce, Daniel, Benson, Paul, Nahass, Ronald, Olson, Carolyn, Wool, G. Michael, Cheung, T W, Jayaweera, D T, Pearce, D, Benson, P, Nahass, R, Olson, C, Wool, G M |
|---|---|
| Předmět: |
HYDRATION
HIV CYTOMEGALOVIRUS diseases NEPHROTOXICOLOGY CREATININE AIDS complications CYTOMEGALOVIRUS disease treatment DRUG therapy for AIDS AIDS ANTIVIRAL agents CLINICAL trials COMPARATIVE studies FLUID therapy INTRAVENOUS therapy RESEARCH methodology MEDICAL cooperation ORAL drug administration RESEARCH SALT AIDS-related opportunistic infections EVALUATION research RANDOMIZED controlled trials DISEASE complications AIDS treatment |
| Zdroj: | International Journal of STD & AIDS; Oct2000, Vol. 11 Issue 10, p640-647, 8p, 5 Charts, 2 Graphs |
| Abstrakt: | We undertook a study to compare the safety of intravenous (i.v.) versus oral hydration to prevent nephrotoxicity associated with the use of foscarnet for induction therapy of cytomegalovirus (CMV) infection in HIV-infected persons. Patients, given foscarnet at a dose of 90 mg/kg every 12 h, were randomized to receive either i.v. or oral hydration. Thirty-seven patients were given i.v. hydration and 44 were given oral hydration. Median duration of therapy for both groups was 17 days. There was no difference between the 2 groups in either serious adverse events or rise of creatinine to > or = 2.0 mg/dl. However, serum creatinine, while generally remained within normal limits, increased more in patients who received oral hydration after 10 days of therapy (significant only by slope analysis, P < 0.05). Although i.v. hydration provided better protection against nephrotoxicity, oral hydration was relatively safe and convenient provided that creatinine clearance (CrCl) is monitored closely. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|